Ingredient

Linagliptin Besylate

Linagliptin benzoate is a blood glucose control ingredient used in the treatment of type 2 diabetes.

All medicines
26
Single ingredient
4
Combination
22
Prescription medication
26

MFDS ingredient code M283624

What does it do?

Linagliptin benzoate is a diabetes treatment component belonging to the DPP-4 inhibitor class. This ingredient promotes insulin secretion and is used to lower blood glucose levels. It is primarily prescribed to help control blood glucose in patients with type 2 diabetes.

Linagliptin benzoate inhibits the DPP-4 enzyme in the body, preventing the degradation of incretin hormones. This results in increased insulin secretion and effective blood glucose regulation. It also decreases glucagon secretion, which inhibits blood glucose elevation.

Commonly used for

Approved uses differ by product. Check each product's information for its actual use.

Good to know

Unlike other DPP-4 inhibitors, linagliptin is primarily metabolized in the liver and has minimal renal excretion, making it relatively safe for use in patients with reduced kidney function. Additionally, there is less weight gain associated with long-term use.

Medicines containing this ingredient

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Category
Dosage form
Strength
Category

26 total

Even with the same ingredient, dosage and approved uses can differ by strength, dosage form and combined ingredients. Check each product's information before taking it.

Combined ingredients

Ingredients used together with this ingredient in combination products.

Questions about this ingredient

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.